Catheter Precision (NYSE: VTAK) to buy $1M stake in Volato stock

Rhea-AI Filing Summary

Catheter Precision, Inc. entered a Securities Purchase Agreement to buy 2,941,176 shares of Volato Group, Inc. common stock in a private placement at $0.34 per share, for a total Subscription Amount of $1,000,000. As of June 5, 2026, the market value of these Volato securities was approximately $1,000,000.

As consideration for participating, Catheter Precision will receive certain freely tradeable equity securities of a third-party entity from Volato, which had an aggregate market value of about $1,100,000 as of June 5, 2026. Closing is subject to customary conditions, including accuracy of representations, covenant performance, and no Material Adverse Effect for Volato.

Under a related Registration Rights Agreement, Volato must file a registration statement on Form S-3 (or other appropriate form) to cover resale of the shares within 10 calendar days and use best efforts to have it declared effective under specified timing. The agreements include customary covenants, indemnities, and registration procedures.

Insights

Corporate finance analyst

Catheter Precision commits $1M to Volato shares and receives third-party equity, with standard protections and resale registration.

Catheter Precision is allocating $1,000,000 to acquire 2,941,176 Volato shares at $0.34 in a private placement. As of June 5, 2026, both the Volato shares and the Subscription Amount line up at roughly $1,000,000 in market value.

In return for joining the deal, Catheter Precision is also receiving freely tradeable third-party equity from Volato, valued around $1,100,000 on that date. Economic impact will ultimately depend on future trading prices and the ability to liquidate these positions.

The Registration Rights Agreement requires Volato to quickly register the resale of the shares on Form S-3 and pursue effectiveness within specified trading-day windows. These provisions, along with customary indemnities and Material Adverse Effect closing conditions, structure the transaction but do not by themselves indicate its eventual financial outcome.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Volato shares purchased: 2,941,176 shares Per-share purchase price: $0.34 per share Subscription Amount: $1,000,000 +4 more

7 metrics

Volato shares purchased 2,941,176 shares Common stock acquired in private placement

Per-share purchase price $0.34 per share Price for Volato common stock

Subscription Amount $1,000,000 Aggregate purchase price for Volato shares

Volato shares market value $1,000,000 Approximate market value as of June 5, 2026

Third-party equity value $1,100,000 Approximate market value as of June 5, 2026

Registration filing deadline 10 calendar days Time for Volato to file initial registration statement

Effectiveness deadline 5 trading days After notice that registration will not be reviewed

Key Terms

Securities Purchase Agreement, private placement, Registration Rights Agreement, registration statement on Form S-3, +2 more

6 terms

Securities Purchase Agreement financial

"Catheter Precision, Inc. entered into a Securities Purchase Agreement between Volato Group, Inc., the Company, and other investors"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

private placement financial

"for an aggregate purchase price of $1,000,000 in a private placement transaction"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

Registration Rights Agreement financial

"the Company entered into a Registration Rights Agreement with Volato"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

registration statement on Form S-3 regulatory

"Volato agreed to file an initial registration statement on Form S-3 with the Commission"

A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.

Material Adverse Effect financial

"the absence of a Material Adverse Effect (as defined in the Purchase Agreement) with respect to Volato"

A material adverse effect is a significant negative change or event that substantially reduces a company’s business, financial condition, or future prospects — think of it like a sudden major engine failure that makes a car unreliable. Investors care because such an event can lower expected profits, trigger contract clauses (allowing counterparties to renegotiate or walk away), and prompt swift stock-price reassessment based on the higher risk and uncertainty.

liquidated damages financial

"The Registration Rights Agreement contains customary provisions relating to registration procedures, registration expenses, liquidated damages and indemnification"

A pre-agreed sum that one party must pay if it breaks a contract, chosen so both sides avoid arguing over the exact amount of loss later. Think of it like a fixed cancellation fee for a reservation: it makes potential costs predictable. For investors, liquidated damages matter because they create a known financial liability that can affect cash flow, contract risk, balance-sheet exposure and deal valuations.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001716621 0001716621 2026-06-07 2026-06-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2026

Catheter Precision, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38677		38-3661826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1670 Highway 160 West Suite 205 Fort Mill, SC		29708
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (973) 691-2000

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		VTAK		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Purchase Agreement

On June 7, 2026, Catheter Precision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) between Volato Group, Inc. (NYSE American: SOAR), a Delaware corporation (“Volato”), the Company, and other investors party thereto, pursuant to which the Company agreed to purchase 2,941,176 shares of common stock, par value $0.0001 per share, of Volato (“Shares”) at a per share purchase price of $0.34 per share, for an aggregate purchase price of $1,000,000 (the “Subscription Amount”), in a private placement transaction (the “Private Placement”). As of June 5, 2026, the aggregate closing price of these securities had a market value of approximately $1,000,000.  However, there is no guaranty the Company will realize the current value of these securities through future sales.  The closing of the Private Placement (the “Closing”) will occur upon the satisfaction or waiver of customary closing conditions set forth in the Purchase Agreement, including the accuracy of the representations and warranties of each party, the performance of each party’s covenants, and the absence of a Material Adverse Effect (as defined in the Purchase Agreement) with respect to Volato. As consideration for the Company’s participation in the Private Placement, Volato has agreed to deliver to the Company certain freely tradeable equity securities of a third-party entity, as further described in the Purchase Agreement.  As of June 5, 2026, the aggregate closing price of these securities had a market value of approximately $1,100,000.  However, there is no guaranty the Company will realize the current value of these securities through future sales.

The Purchase Agreement contains customary mutual representations and warranties, covenants of Volato, and indemnification provisions by Volato.

Registration Rights Agreement

In connection with the Private Placement, on June 7, 2026, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Volato. Pursuant to the Registration Rights Agreement, Volato agreed to file an initial registration statement on Form S-3 (or such other appropriate form if Form S-3 is not available) with the U.S. Securities and Exchange Commission (the “Commission”) covering the resale of the Shares no later than the 10th calendar day following the date of the Registration Rights Agreement, and to use its best efforts to cause such registration statement to be declared effective by the Commission as promptly as possible after the filing thereof, but in any event no later than the fifth trading day after the date Volato is notified by the Commission that the registration statement will not be reviewed or will not be subject to further review.

The Registration Rights Agreement contains customary provisions relating to registration procedures, registration expenses, liquidated damages (subject to certain carve-outs) and indemnification.

The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)         Exhibits.

Exhibit No.	Description
10.1	Securities Purchase Agreement, dated as of June 7, 2026, by and between Volato Group, Inc. and Catheter Precision, Inc.
10.2	Registration Rights Agreement, dated as of June 7, 2026, by and between Volato Group, Inc. and Catheter Precision, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 8, 2026

	CATHETER PRECISION, INC.
	By:	/s/ Philip Anderson
		Philip Anderson
		Chief Financial Officer

FAQ

What transaction did Catheter Precision (VTAK) announce with Volato Group?

Catheter Precision agreed to buy 2,941,176 Volato common shares for a total Subscription Amount of $1,000,000 in a private placement, under a Securities Purchase Agreement dated June 7, 2026, alongside customary closing conditions and related registration rights.

How many Volato shares is Catheter Precision (VTAK) purchasing and at what price?

Catheter Precision is purchasing 2,941,176 Volato common shares at a price of $0.34 per share. This results in a total Subscription Amount of $1,000,000 for the private placement, assuming the transaction closes under the agreed terms and conditions.

What additional consideration does Catheter Precision receive in the Volato private placement?

As consideration for participating, Catheter Precision will receive freely tradeable equity securities of a third-party entity from Volato. These securities had an approximate aggregate market value of $1,100,000 based on closing prices as of June 5, 2026, subject to future market performance.

What are the key closing conditions for Catheter Precision’s Volato investment?

Closing depends on customary conditions, including accurate representations and warranties by each party, performance of their covenants, and the absence of a Material Adverse Effect with respect to Volato, all defined within the Securities Purchase Agreement dated June 7, 2026.

What registration obligations does Volato have under the agreement with Catheter Precision (VTAK)?

Volato must file an initial registration statement on Form S-3, or another suitable form, to cover resale of the purchased shares within 10 calendar days, and use best efforts to have it declared effective within a short, specified trading-day window, under the Registration Rights Agreement.

How is the resale of the Volato shares Catheter Precision buys being facilitated?

Resale is supported by a Registration Rights Agreement. Volato agreed to register the shares on Form S-3, cover registration procedures and expenses, and include provisions on liquidated damages, subject to carve-outs, and indemnification, helping enable future public resale by Catheter Precision.

Filing Exhibits & Attachments

6 documents

Agreements & Contracts

• EX-10.1 EXHIBIT 10.1 SOAR PIPE SPA COMMON STOCK 223.9 KB
• EX-10.2 EXHIBIT 10.2 SOAR PIPE RRA - COMMON STOCK 162.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.5 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.7 KB